Yao-Wen Cheng1, Monika Fischer2. 1. Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. 2. Division of Gastroenterology, Department of Medicine, Indiana University School of Medicine, 550 N. University Blvd, Suite 1602, Indianapolis, IN, 46202, USA. mofische@iu.edu.
Abstract
OPINION STATEMENT: PURPOSE OF REVIEW: This article will review current literature describing fecal microbiota transplantation (FMT) in the treatment of various diseases, and its potential role in elderly patients (age ≥ 65 years). RECENT FINDINGS: Research on FMT has blossomed in the last decade and its pivotal role in the treatment of recurrent Clostridium difficile infection (CDI) has been recognized by the American College of Gastroenterology in the latest guidelines. There is also emerging evidence that FMT may be beneficial in the treatment of severe and/or complicated CDI refractory to medical therapy, resulting in decreased rates of colectomy and mortality. In the elderly, CDI is associated with markedly higher rates of mortality and colectomy; outcomes are even worse when patients have underlying inflammatory bowel disease (IBD). While the majority of patients who receive FMT for CDI are older, only a handful of studies focused specifically on FMT treatment outcomes and safety in this age group. Current data corroborate the efficacy and safety profile of FMT, while also supporting its use for recurrent, severe, and/or complicated CDI in the elderly population. FMT is recommended for the treatment of recurrent, severe, and/or complicated CDI in patients older than 65 years of age. It may be prudent to offer FMT earlier in the disease course, possibly after just the second recurrence and for the first episode of severe CDI to avert complications including colectomy and end-organ failure that elderly patients are more prone to developing.
OPINION STATEMENT: PURPOSE OF REVIEW: This article will review current literature describing fecal microbiota transplantation (FMT) in the treatment of various diseases, and its potential role in elderly patients (age ≥ 65 years). RECENT FINDINGS: Research on FMT has blossomed in the last decade and its pivotal role in the treatment of recurrent Clostridium difficileinfection (CDI) has been recognized by the American College of Gastroenterology in the latest guidelines. There is also emerging evidence that FMT may be beneficial in the treatment of severe and/or complicated CDI refractory to medical therapy, resulting in decreased rates of colectomy and mortality. In the elderly, CDI is associated with markedly higher rates of mortality and colectomy; outcomes are even worse when patients have underlying inflammatory bowel disease (IBD). While the majority of patients who receive FMT for CDI are older, only a handful of studies focused specifically on FMT treatment outcomes and safety in this age group. Current data corroborate the efficacy and safety profile of FMT, while also supporting its use for recurrent, severe, and/or complicated CDI in the elderly population. FMT is recommended for the treatment of recurrent, severe, and/or complicated CDI in patients older than 65 years of age. It may be prudent to offer FMT earlier in the disease course, possibly after just the second recurrence and for the first episode of severe CDI to avert complications including colectomy and end-organ failure that elderly patients are more prone to developing.
Authors: G Cammarota; L Masucci; G Ianiro; S Bibbò; G Dinoi; G Costamagna; M Sanguinetti; A Gasbarrini Journal: Aliment Pharmacol Ther Date: 2015-03-01 Impact factor: 8.171
Authors: Theodore R Levin; Wei Zhao; Carol Conell; Laura C Seeff; Diane L Manninen; Jean A Shapiro; Jane Schulman Journal: Ann Intern Med Date: 2006-12-19 Impact factor: 25.391
Authors: Ilan Youngster; Jenny Sauk; Christina Pindar; Robin G Wilson; Jess L Kaplan; Mark B Smith; Eric J Alm; Dirk Gevers; George H Russell; Elizabeth L Hohmann Journal: Clin Infect Dis Date: 2014-04-23 Impact factor: 9.079
Authors: Amelia M Kasper; Humaa A Nyazee; Deborah S Yokoe; Jeanmarie Mayer; Julie E Mangino; Yosef M Khan; Bala Hota; Victoria J Fraser; Erik R Dubberke Journal: Infect Control Hosp Epidemiol Date: 2012-03-20 Impact factor: 3.254
Authors: Kaouther Ben-Amor; Hans Heilig; Hauke Smidt; Elaine E Vaughan; Tjakko Abee; Willem M de Vos Journal: Appl Environ Microbiol Date: 2005-08 Impact factor: 4.792
Authors: Manasi Agrawal; Olga C Aroniadis; Lawrence J Brandt; Colleen Kelly; Sarah Freeman; Christina Surawicz; Elizabeth Broussard; Neil Stollman; Andrea Giovanelli; Becky Smith; Eugene Yen; Apurva Trivedi; Levi Hubble; Dina Kao; Thomas Borody; Sarah Finlayson; Arnab Ray; Robert Smith Journal: J Clin Gastroenterol Date: 2016 May-Jun Impact factor: 3.062